Table 4.

AEs of anti-PD-1/PD-L1 antibody therapy

AE	All patients (n = 18), n (%)
	any grade	grade 3/4
Pruritus	8 (44)	0 (0)
Proteinuria	1 (6)	0 (0)
Diarrhea	1 (6)	0 (0)
Decreased appetite	0 (0)	0 (0)
Fatigue	0 (0)	0 (0)
Liver injury or failure	5 (28)	1 (6)
Encephalopathy	0 (0)	0 (0)
Jaundice	1 (6)	1 (6)
Hypoalbuminemia	0 (0)	0 (0)
Ascites	2 (11)	0 (0)
Peripheral edema	1 (6)	0 (0)
Bleeding or hemorrhage	3 (17)	1 (6)
Hypothyroidism	1 (6)	0 (0)
Arthritis	1 (6)	0 (0)
Hyperglycemia	1 (6)	1 (6)
Adrenal insufficiency	1 (6)	1 (6)
Infection	2 (11)	2 (11)

PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; AE, adverse event.